TGFBI and glioma: BIGH3 in GM-derived exosomes dynamically reflect the efficacy of TMZ (temozolomide) treatment of glioma, while TiO2-related LSPR can track the level of BIGH3 to monitor TMZ’s anti-cancer effect and prognosis after treatment (73).